A Phase 2 interventional study of Darovasertib in Uveal Melanoma, sponsored by IDEAYA Biosciences. Active, not recruiting at 18 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by IDEAYA Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 190 studies in Uveal Melanoma with a site in United States — 25 open to participants now, 50 under way, 7 of them phase 3. Uveal Melanoma · United States.
Among the 190 studies in Uveal Melanoma with a site in United States, this one is the 17th largest by planned enrollment of the 162 interventional ones that give a count, is one of 7 that started in 2023, is one of 79 in phase 2, reaches primary completion later than 20 of the 49 other live ones, and was the 166th registered.
281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.
Browse Uveal Melanoma studies →25 of the 190 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:
IDEAYA Biosciences · Sites in United States, Australia, Canada and 3 more countries
Ages 18+
VM Discovery, Inc. · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18+
IDEAYA Biosciences · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
190 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 73 · Phase 2 101 · Phase 3 12 · Phase 4 1
First in 1996; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 37 across 222 interventional studies indexed under Uveal Melanoma.
Median enrollment 36 across the 162 interventional studies, 79 across the 18 observational. Of the 130 that completed or were terminated, 58 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 190 have an industry lead sponsor. The 10 most frequent:
IDEAYA Biosciences is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
IDEAYA Biosciences has 5 studies filed under Uveal Melanoma — fewer than ten, so there is no comparison to draw.
16 of the studies in Uveal Melanoma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06007690Phase 3Aura BiosciencesA Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | 2027-11-15 |
| NCT01587352National Cancer Institute (NCI)Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | 2026-12-31 |
| NCT03947385IDEAYA BiosciencesStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | 2027-01-29 |
| NCT04728633Thomas Jefferson UniversityTransarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases | 2027-01-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 190 studies in Uveal Melanoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma (UM) requiring either enucleation or plaque brachytherapy. Patients will be treated in neoadjuvant setting up to 12 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment may be given to some patients. All patients will have long term follow-up (up to 3 years) to assess visual outcome, disease recurrence, and development of metastatic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IDE196 (darovasertib) oral open label
Drug: Darovasertib
Oral, potent, selective inhibitor of Protein Kinase C
Also known as: IDE196, LXS196
Incidence of Adverse Events (AEs) and significant laboratory abnormalities
Treatment emergent adverse events will be summarized by all AEs, all Grade 3-4-5 AEs, all treatment related AEs, all AEs leading to study drug modifications or discontinuations, all SAEs. Lab results will be summarized by change from baseline values, frequency of newly occurring on-treatment Grade 3 or 4 events; worst on-treatment value compared to baseline.
Time frame: from first dose to 28 days after last dose of therapy, approximately 18 months
Cohort 1 (enucleation): Number of patients converted from requiring enucleation to radiation
Rate of eye salvage as determined by the ocular oncologist based on tumor response to neoadjuvant therapy
Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
Cohort 2 (plaque brachytherapy): Estimated change in modeled radiation dose
Change in modeled radiation dose at critical eye structures before and after neoadjuvant therapy
Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
Cohort 3 (patients with small UM tumors): Number of patients with clinical benefit per protocol-defined UM response criteria
Proportion of patients with clinical benefit rate (CBR) defined as complete response (CR) + partial response (PR) + stable disease (SD) for ≥ 12 weeks per UM response criteria
Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
Evaluate tumor response to neoadjuvant IDE196
Measurement of tumor diameter and thickness before and after neoadjuvant therapy with IDE196, specifically as measured by ocular ultrasound, evaluating largest basal diameter and apical thickness of the uveal melanoma (measured in millimeters)
Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
Assessment of visual acuity loss
Best corrected visual acuity loss over time
Time frame: from time of primary local therapy to one year after surgery, approximately 12 months
Rate of local disease recurrence
Evaluate uveal melanoma progression or recurrence
Time frame: from date of primary local therapy to end of follow-up, approximately 36 months
Cohort 3 (patients with small UM tumors): Effect of neoadjuvant IDE196 therapy on the natural history of small UM tumors
Time from first dose of neoadjuvant to primary local therapy
Time frame: from first dose of neoadjuvant to primary local therapy, approximately 12 months
Cohort 3 (patients with small UM tumors): Efficacy of neoadjuvant IDE196 therapy on small UM tumors
Tumor response (complete response and partial response) as measured by protocol-defined UM response criteria
Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
Rate of metastatic disease
Evaluate occurrence of metastatic uveal melanoma
Time frame: from date of primary local therapy to end of follow-up, approximately 36 months
Overall survival
Evaluate patient survival status
Time frame: from date of first dose to end of follow-up, approximately 54 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Apr 2027, 45 months after the start.
Of 46 phase 2 interventional studies under Uveal Melanoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 45 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Darovasertib
IDEAYA Biosciences